Bladder Cancer
Prostate Cancer
EAU Edu Platform on Kidney Cancer
Home
Articles
Article of the Month
Editorials
Videos
Webcasts
Education
E-courses
Webinars
Online curriculum
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorials
Videos
Webcasts
Education
Terug
E-courses
Webinars
Online curriculum
Guidelines
Events
Upcoming event
40th Annual EAU Congress
Home
/
ASCO GU22
Back
Tag:
ASCO GU22
CYTOSHRINK study
View
ASCO GU 2022 RCC recommendations
View
TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
View
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)
View
SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer
View
ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations
View
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)
View
